NRX Pharmaceuticals (NRXP) Tax Provisions (2018 - 2024)

NRX Pharmaceuticals (NRXP) posted quarterly Tax Provisions of $3000.0 for Q3 2024, up 156.01% quarter-over-quarter from -$5356.0 in Q4 2020.

NRX Pharmaceuticals (NRXP) Tax Provisions (2018 - 2024) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Tax Provisions for 4 consecutive years, with $3000.0 the latest figure, recorded in Q3 2024.

In Q3 2024, Tax Provisions changed N/A year-over-year to $3000.0; the TTM figure through Sep 2025 stood at $3000.0 (changed 0.0% YoY), while the FY2020 annual figure was $17841.0, down 82.57% from the prior year.
Tax Provisions grew to $3000.0 in Q3 2024 per NRXP's latest filing, from -$5356.0 in the prior quarter.
Across five years, Tax Provisions topped out at $72628.0 in Q1 2020 and bottomed at -$42690.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	-

Download Data